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Abstract
Considerable arguments remain regarding the diverse biological activities of polyunsaturated fatty acids (PUFA).
One of the most interesting but controversial dietary approaches focused on the diverse function of dihomo-
dietary g-linolenic acid (DGLA) in anti-inflammation and anti-proliferation diseases, especially for cancers. This
strategy is based on the ability of DGLA to interfere in cellular lipid metabolism and eicosanoid (cyclooxygenase
and lipoxygenase) biosynthesis. Subsequently, DGLA can be further converted by inflammatory cells to 15-(S)-
hydroxy-8,11,13-eicosatrienoic acid and prostaglandin E1 (PGE1). This is noteworthy because these compounds
possess both anti-inflammatory and anti-proliferative properties. PGE1 could also induce growth inhibition and
differentiation of cancer cells. Although the mechanism of DGLA has not yet been elucidated, it is significant to
anticipate the antitumor potential benefits from DGLA.
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Supplementation of cell cultures in vitro or feeding ani-
mals with ω-3 or ω-6 polyunsaturated fatty acids
(PUFAs) led to an increase of these PUFAs in cell mem-
brane phospholipids and may influence membrane prop-
erties [1,2]. Moreover, PUFAs and their metabolites,
eicosanoids, are considered as important mediators and
modulators of the intracellular network of signals [3],
they change oxidative metabolism and may have a direct
effect on gene expression when activating the specific
nuclear receptors and transcription factors [3-5]. ω-3
types PUFAs were reported to improve immunological
response, prevent proliferation and initiate apoptosis,
kill tumor cells in vitro [6-8], and inhibit tumor growth
in experimental animals, while ω-6 PUFAs are supposed
not to possess such significant antitumor effects even
generate opposite action [9,10].
One of the most interesting but controversial dietary
approaches focused on the diverse function of dihomo-
dietary g-linolenic acid (DGLA) in anti-inflammation
and anti-proliferation diseases although it is a distinct
ω-6 type PUFA [11-13]. To evaluate DGLA-related
nutraceuticals critically, it is essential to elucidate the
mechanisms underlying the relationship between DGLA
and health maintenance. This review will focus on
recent studies that address the physiologic functions and
mechanisms of function of DGLA in proliferation and
hyperplasia diseases.
Dihomo-g-linolenic acid (DGLA) is a 20-carbon ω-6
polyunsaturated fatty acid (PUFA) derived in vivo from
linolenic acid, an essential fatty acid. DGLA can then be
converted to arachidonic acid (AA), another 20-carbon
ω-6 PUFA [11,12]. Both DGLA and AA are substrates
of the lipid-peroxidizing enzyme COX. Through a series
of free radical reactions, COX metabolizes DGLA and
AA to form various bioactive metabolites, namely, the 1
and the 2 series of prostaglandins (PGs1 and PGs2),
respectively. Unlike PGs2, which are generally viewed as
pro-inflammatory, PGs1 actually possess anti-inflamma-
tory and anticancer activities [14-16]. For example,
PGE1, one form of PGs1, could inhibit vascular smooth
muscle cell proliferation, reduce vascular cell adhesion,
and attenuate the development of atherosclerosis
[17-19].
DGLA metabolism
It is generally thought that all mammals, including
humans, require 1-2% of total dietary energy as linoleic
acid [LA, 18:2(n-6)] to prevent essential fatty acid
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any medium, provided the original work is properly cited.deficiency [12]. LA is metabolized in a variety of tissues
by Δ6 desaturase to form GLA, which is rapidly elon-
gated to DGLA (Figure 1). DGLA can be further desatu-
rated to arachidonic acid [AA, 20:4(n-6)] by Δ5
desaturase. However, due to the limited activity of Δ5
desaturase in rodents and humans, only a partial DGLA
is converted to AA [20,21]. These data indicate that in
many cell types, DGLA, the elongase product of GLA,
but not AA, accumulates after GLA supplementation.
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attenuate the biosynthesis of AA metabolites, i.e., 2-ser-
ies prostaglandins, 4-series leukotrienes and platelet-
activating factor (PAF), and exerts an anti-inflammatory
effect in human subjects [20-22] (Figure 1). Another
research demonstrated that addition of GLA or DGLA
together with a mixed D5/D6 fatty-acid desaturase inhi-
bitor CP-24879 inhibited D5 desaturase activity and the
further conversion of DGLA into AA. This led to a very
substantial increase in the accumulation of DGLA from
2.3% to almost 12% of total fatty acids without a change
in the level of AA [16].
In addition, because addition of DGLA bypasses a key
regulatory rate-limiting enzymatic step (Δ6 desaturase)
which controls the formation of long-chain PUFA of the
(ω-6) series, it may generate a systemic decline in Δ6
desaturation. Researches has confirmed that a reduced
capacity to convert LA to DGLA has been associated
with various physiologic and pathophysiologic states,
including aging, diabetes, alcoholism, atopic dermatitis,
premenstrual syndrome, rheumatoid arthritis, cancer
and cardiovascular disease [12,17,23]. Therefore, supple-
mentation of DGLA may be of value in alleviating some
of the symptoms of these various diseases.
DGLA metabolic oxidation and mechanisms against
proliferation diseases
Alteration in the dietary content of fatty acids can lead to
modulation of the structure/function of membrane-bound
receptors, cell-cell interaction, enzyme activities, cellular
signalling and eicosanoid production [24,25]. Eicosanoid
synthesis is dependent on the size of the fatty acid precur-
sor pool(s) and on the availability of substrate fatty acids
released from phospholipids [26,27]. Depending on the
cell types, DGLA is cyclooxygenated (by COX-1/2) to
prostaglandins of the 1-series (PGE1) and/or metabolized
by the 15-lipoxygenase into 15-(S)-hydroxy-8,11,13-eicosa-
trienoic acid (15-HETrE) [28] (Figure 1, 2). These two oxi-
dative metabolites of DGLA, have been found to exert
clinical efficacy in a variety of diseases, including suppres-
sion of chronic inflammation, vasodilation and lowering of
blood pressure, inhibition of smooth muscle cell prolifera-
tion associated with atherosclerotic plaque development,
arresting of cancer cell growth and the differentiation of
tumor cells [15,29-31].
Figure 1 Products of dihomo-g-linolenic acid. In mammal tissues and cells, DGLA is converted to AA by an alternating sequence of Δ5
desaturation. DGLA can be converted to PG1 via the cyclooxygenase pathway and/or converted to 15-HETrE via the 15-lipoxygenase pathway.
During the process of conversion mediated by different oxygenases, free radicals and lipid perioxidation and various metabolites were
generated.
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synthesis, is one of the interesting cellular factors and has
been suggested to be associated with carcinogenesisin col-
orectal cancer [32-34]. The contribution of COX-2 to
tumorigenesis includes an increased resistance to apopto-
tic stimuli, enhanced invasiveness, and stimulated angio-
genesis [14,32-35]. In addition, expression of COX-2 has
also been found to be high in other types of cancers
including prostate, breast, gastric, pancreatic, liver, lung,
and skin cancers [36-42]. COX enzymes are integralmem-
brane proteins located in the endoplasmic reticulumand
nuclear membrane. These proteins are known to catalyze
the rate-limiting step in the metabolism of arachidonic
acid (AA), resulting in the production of prostaglandin G2
(cyclooxygenase reaction) [16,43]. Prostaglandin G2 is
then converted to prostaglandin H2 (peroxidase reaction),
a target of several specific prostanoid synthases, resulting
in the production of prostaglandins, prostacyclins, and
thromboxanes [43,44]. Two COX isoforms have been
identified. COX-1 is constitutively expressed in most nor-
mal mammalian tissues,where it is involved in the mainte-
nance of tissue homeostasis.In contrast, COX-2 is rapidly
expressed as a consequence of stimulation by growth fac-
tors, cytokines, inflammatory mediators, and tumor pro-
moters [44,45]. While a paradoxical aspect of COX-2 is
that it could also convert DGLA to PGE1 which possesses
anti-inflammation, anti-proliferation and promoting differ-
entiation capacity [45]. It seemed that the ratio of PGE1/
PGE2 mediated by COX-2 produced a balance efficancy
on cell growth.
The majority of prostaglandins, including PGE1, PGE2,
PGI2, PGD2, PGF2, and TXA2, are quickly secreted from
cells and bind locally to membrane-bound prostanoid
receptors termed EP, IP, DP, FP, and TP, respectively.
Figure 2 Metabolism of dihomo-g-linolenic acid. In mammal tissues and cells, LA is converted to AA by an alternating sequence of Δ6
desaturation, chain elongation and Δ5 desaturation. Dietary GLA bypasses the rate-limited Δ6 desaturation step and is quickly elongated to
DGLA by elongase, with only a very limited amount being desaturated to AA by Δ5 desaturase. DGLA can be converted to PGE1 via the
cyclooxygenase pathway and/or converted to 15-HETrE via the 15-lipoxygenase pathway.
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subtypes EP1, EP2, EP3, and EP4 [46]. With regard to
tumor biology, the prostanoid PGE2 stimulates the
growth and invasion of several different tumor cells and
promotes angiogenesis by increasing VEGF production
[47-49]. In comparison, PGE1 possesses distinct anti-
inflammation and anti-proliferation action [15,50]. GLA
or DGLA supplementation studies conducted in humans
and rodents have shown that the synthesis of 1-series
prostaglandins, and not the 2-series prostaglandins
(PGE2, derived from AA), is selectively elevated [16,17].
Although the increases in the tissue levels of PGE1 after
DGLA supplementation are modest relative to PGE2,
effects are noteworthy because select biological proper-
ties of PGE1 are ~20 times stronger than PGE2 [51]. In
particular, PGE1 elicits an array of intracellular
responses by binding to select G protein coupled surface
PGE (EP) receptors and/or the prostacyclin (IP) receptor
[52]. Four subtypes of the EP-receptor, termed EP1,E P 2,
EP3 and EP4 have been identified. The EP2,E P 4 and IP
receptors couple to adenylatecyclase via a Gs-protein,
and receptor activation results in increases in intracellu-
lar levels of cyclic 3’,5’-adenosine monophosphate
(cAMP) [52,53]. This in turn stimulates the expression
of numerous genes through the PKA-mediated phos-
phorylation of the nuclear CREB binding proteins. The
transcriptional co-activator, CBP, in turn, mediates
PKA-induced transcription by binding to the PKA phos-
phorylated activation domain of CREB. CREB proteins
can also heterodimerize with other members of the b-
Z I Po rb a s i cz i p p e rf a m i l yo ft r a n s c r i p t i o nf a c t o r s ,
including Fos proteins (c-fos, Fosb, Fra-1, Fra-2), and
Jun proteins (c-jun, JunB, JunD). Elevation of cAMP sti-
mulates the expression of numerous genes through the
protein kinase A (PKA)-mediated phosphorylation of
the nuclear cAMP response element binding proteins
(CREB). Through this mechanism, PGE1 has been
shown to inhibit vascular smooth muscle cell (SMC)
proliferation in vitro [53,54]. It is significant because
reducing the migration and proliferation of vascular
SMC could arrest the formation of the typical athero-
sclerotic plaque [55,56]. The question of whether PGE1
and PGE2 act on the same or different receptors is not
yet resolved. Some reports provide data to demonstrate
that PGE1 binds to the PGE2 receptors EP2 and EP4
[57,58], indicating that PGE1 could compete with PGE2
through binding to the same receptors.
More encouraging researches indicate that several dis-
eases may benefit from GLA or DGLA administration
[12,17,20-22]. It is reported that GLA or DGLA sup-
presses human synovial cell proliferation in culture by
increasing PGE1 synthesis and intracellular cAMP levels
[59]. In addition, administration of GLA or DGLA is
capable of suppressing human T-cell proliferation
[12,60]. Although the precise mechanism of responses
remains to be investigated, it has been suggested that
the incorporation of select diet-derived PUFA may alter
the dynamic lipid environment that influences protein
lateral diffusion of anchored receptors, thereby modulat-
ing their function [2,3]. These findings highlight the
need for establishing a therapeutic GLA or DGLA dose
that will down-regulate autoimmune and cell-mediated
responses.
Detection of the oxidative metabolism of DGLA into
lipoxygenase products has shown that some cell types,
including neutrophils, macrophage/monocytes and epi-
dermal cells, metabolize DGLA into the 15-lipoxygenase
product, 15-HETrE. Researches suggest that 15-lipoxy-
genase-derived hydroxy fatty acids inhibit the synthesis
of AA-derived 5-lipoxygenase metabolites [11,12,28]
(Figure 3). The observations are significant because ele-
vated levels of AA-derived 5-lipoxygenase products, e.g.,
LTC4 and LTB4, are associated with several pathologic
inflammatory, hyperproliferative disorders [61,62]. Stu-
dies also indicate that 15-HETrE can be incorporated
into the membrane phospholipid, phosphatidylinositol
4,5-bisphosphate (PtdIns 4,5-P2), and released as 15-
HETrE-containing-diacylglycerol (15-HETrE-DAG)
[63,64]. Interestingly, 15-HETrE-DAG is able to inhibit
protein kinase C b (PKC b), a mediator of the cell cycle
in select cell types [63]. The inhibitions of leukotriene
biosynthesis and PKC-dependent signal transduction are
probable mechanisms by which DGLA exertsanti-
inflammation and anti-proliferative responses. It is gen-
erally thought that DGLA-derived eicosanoid (PGE1 and
15-HETrE) biosynthesis is dependent primarily on the
abundance of nonesterified DGLA, so increasing the
administration of DGLA may be a good strategy to treat
some proliferation diseases.
Efficacy of DGLA against tumors
A growing number of studies suggest that DGLA is
unique among the (n-6) PUFA family members (LA,
GLA and AA) in its potential to suppress tumor growth
and metastasis. DGLA has the ability to inhibit both
motility and invasiveness of human colon cancer cells
by increasing the expression of E-cadherin, a cell-to-cell
adhesion molecule that acts as a suppressor of metasta-
sis [65,66]. In addition, DGLA reduces tumor-endothe-
lium adhesion, a key factor in the establishment of
distant metastases, partly by improving gap junction
communication within the endothelium [65,67]. These
encouraging results indicate that further investigations
should be given priority.
Since PUFAs enhance free radical generation and lipid
peroxidation process and thus, induce apoptosis, it sug-
gests that these events lead to depletion of ATP levels
in the tumor cells which brings about their death. This
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peroxidation process, apoptosis and genes/oncogenes
that regulate apoptotic process [6-10]. Researches pre-
viously have showed that some polyunsaturated fatty
acids (PUFAs) induced apoptosis of tumor cells with lit-
tle or no cytotoxic action on normal cells under certain
conditions [6,68,69]. It was observed that of all the fatty
acids tested, GLA or DGLA was the most effective in
selectively killing the tumor cells [6]. In a co-culture
experiment wherein normal human skin fibroblasts and
human breast cancer cells were grown together in a
petri dish supplemented with GLA or DGLA, only
human breast cancer cells were eliminated without any
effect on normal skin fibroblasts [65,68,70,71]. These
results reconfirmed that GLA or DGLA show selective
tumoricidal action at least in vitro. These molecular
changes were found to be significantly associated with
enhanced degree of lipid peroxidation in the fatty acid
supplemented tumor cells [6,65,68-71]. GLA and DGLA
were also found to be capable of suppressing the expres-
sion of oncogenes Her-2/neu and Bcl-2 and enhance
p53 activity and thus, induce apoptosis of tumor cells
[72-74]. In an extension of these studies, it was noted
that cyclooxygenase and lipoxygenase inhibitors blocked
the tumoricidal action of DGLA on human cervical car-
cinoma; whereas anti-oxidants inhibited cytotoxic action
of DGLA on human breast cancer cells [6,73,75-77].
Prostaglandins (PGE1)f r o mD G L Am e d i a t e db yC O X
inhibited the growth of HeLa cells [77,78]. LOX pro-
ducts were more potent than PGs in inhibiting of HeLa
cell growth which was confirmed by the observation
that a 9-fold increased formation of hydroxides occurred
in HeLa cells [77]. These results suggest that both COX
products, LOX products and free radicals, lipid peroxi-
dation are involved in the tumoricidal action of DGLA.
A significant increase in the formation of free radicals
and lipid peroxides was noted only in tumor cells trea-
ted with DGLA compared to untreated tumor cells
[6-10,75-78], suggesting that the involvement of COX
and LOX products, free radicals and lipid peroxides in
the tumoricidal action of DGLA varies depending on
the cell type that is being tested. Recent studies demon-
strated that the longer-chain n-6 PUFA produced by
GLA feeding decreased the Th2 cytokine and immuno-
globulin (Ig)G1 antibody response. GLA and DGLA
could also induce T-regulatory cell activity, e.g., trans-
forming growth factor (TGF)-beta-producing T cells,
and reduce proinflammatory interleukin (IL)-1 and
Figure 3 Mechanisms of dihomo-g-linolenic acid in anti-proliferation of diseases. DGLA-derived PGE1 has been identified as possessing
anti-inflammatory properties that differentiate it from AA-derived PGE2. DGLA could be metabolized into the 15-lipoxygenase product, 15-HETrE,
which is capable of inhibiting the synthesis of AA-derived 5-lipoxygenase metabolites and further attenuates the pro-inflammatory products from
AA. All types of free radicals (superoxide anion, H2O2, hydroxyl radicals) and lipid peroxides play a role in the induction of apoptosis of tumor
cells by the metabolism of DGLA. Selective COX-2 inhibitor could stop AA from converting to PGE2 which are able to stimulate cancer cell
proliferation. DGLA may be accumulated through blocking the conversion to AA mediated by selective desaturase inhibitor.
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cating immunity mechanism is likely to participate in
the anti-tumor effect.
Drug resistance is a major issue in the management of
cancer. Hence, methods or strategies to prevent and
reverse tumor cell drug resistance are needed. More stu-
dies confirmed that GLA and DGLA could kill drug
resistant tumor cells in vitro and augment tumoricidal
actions of anti-cancer drugs synergistically [6,65,68-71].
But, it is not clear as to the exact mechanism by which
this synergism between anti-cancer drugs and DGLA
occurs. The possible mechanism lies in DGLA could
augment uptake and decrease efflux of anti-cancer drugs
and thus, reverse tumor cell drug resistance [6,75].
However, the mechanism of action mediating DGLA
effects was not fully elucidated, because feeding of GLA
or DGLA as ethyl esters or triglycerides (triacylglycerols)
generally led to only a small increase in GLA or DGLA
content in cell membrane lipids, often accompanied by
a very significant increase in AA content. Furthermore,
the ratio of PGE1/PGE2 produced in cells obtained from
animals fed with GLA-containing oils was shown to be
substantially lower than the cellular ratio of DGLA/AA
[16,17]. Similarly, in studies with cultured mouse fibro-
sarcoma cells rendered deficient in essential fatty acids
and then replenished with either DGLA or AA, the ratio
of synthesized PGE1/PGE2 was considerably smaller
than the cellular ratio of DGLA/AA [80,81]. It should,
however, be pointed out that in both in vivo dietary
study and in vitro cell culture study, the cellular content
of AA, even after significant enrichment with DGLA,
was still 2.5 ± 3-fold higher than DGLA, mainly due to
effective desaturation of DGLA to AA [16,81,82]. There-
fore, an effective solution to accumulate the content of
DGLA is to administer selective Δ5 desaturase inhibitors
to stop DGLA from further converting to AA. Sesame,
curcumin and other analog desaturase inhibitors, for
example, CP-24879, a d5/d6 desaturase inhibitor, have
been verified to exert anti-proliferation or anti-cancer
effect by enhancing the concentration of DGLA
[16,82-84].
While studies showed in some cancer cells, after using
the COX and LOX inhibitor, GLA or DGLA only led to a
partially growth inhibition of cancer cells, which indicates
that the change ratio of PGE1/PGE2 derived from DGLA
metabolites couldn’t completely account for the antitu-
mor effect [6,12,16,17]. Recent research has verified that
free radicals and lipid perioxidation play an important
role in the cytotoxic action to cancer, which could be
completely arrested by anti-oxidants such as vitamin E
and SOD depending on different cell lines [6]. On the
other hand, some reports assume that vitamin E only par-
tially arrests the growth inhibition of cancer cells
mediated by PUFAs [70,73,85]. One of the reasons for
the different experimental results may originate from var-
ious employed cell lines. Another reason is that near all
the cytotoxicity effects against cancer cells depend on the
time and concentrition of the metabolic products from
PUFA. Therefore, DGLA is likely to exert its antitumor
cytotoxic effects from free radicals and lipid perioxidation
and metabolites, which probably inhibit the proliferation,
promote apoptosis and even make cancer cell differenti-
ate and maturation [6-10] (Figure 3). Further investiga-
tion need to confirm the presumption.
Possible adverse effects of oral supplementation with
DGLA
A previous report noted that administration of DGLA
ethyl ester to health volunteer (1 g/d) reduced platelet
aggregation [86]. However, DGLA ethyl ester is an experi-
mental reagent and is not available for practical and nutri-
tional usage. On January 27, 1993, the United States Court
of Appeals for the Seventh Circuit ruled that GLA, con-
taining oil is a single food ingredient and therefore not
subject to food additive regulation. As a result of this legis-
lation, GLA-containing oils (primrose oil, blackcurrant
seed oil and borage oil) have become increasingly popular
with retailers and are being sold as encapsulated supple-
ments [17]. To evaluate DGLA-related nutraceuticals criti-
cally, it is essential to elucidate the mechanisms
underlying the relationship between DGLA and health
maintenance. Recent researches indicated that from
rodent to human, oral supplementation of DGLA-enriched
oil showed no-observed-adverse-effect. In acute and sub-
chronic oral toxicity tests in rats, DGLA oil, ranging from
500, 1000, 2000 mg/kg to 10 g/kg was orally administered.
There was no death in either sex and no toxicological
changes in body weight, food consumption, ophthalmolo-
gical examination, urinalysis, hematological examination,
blood biochemical examination, necropsy, organ weight,
or histopathological examination [87]. The researcher also
compared the dietary effects of DGLA with GLA on the
fatty acid composition. The resulted showed that the
DGLA concentrations in the liver, serum, and brain of the
DGLA group were higher than those of the GLA oil
group. The DGLA levels in the liver, serum, and brain sig-
nificantly increased with increasing dosage of DGLA in
the diet. DGLA administration significantly increased the
ratio of PGE1/PGE2 in the rat plasma. These results sug-
gest that the dietary effect of DGLA would be more domi-
nant than GLA [88]. Further research confirmed the safety
of consumption of DGLA in human. DGLA-enriched oil
(50 or 150 mg as free DGLA) was administered to healthy
men for 4 weeks. The DGLA content in serum phospholi-
pids dose-dependently increased and returned to the initial
level after a 4-week washout. No side effects or changes in
platelet aggregation were observed. These results indicate
that oral supplementation with DGLA oil can safely
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tion of the mechanism(s) of DGLA will lead to the estab-
lishment of dietary guidelines designed to reduce the
incidence and severity of inflammatory or hyperprolifera-
tive diseases.
Conclusions
In summary, regulation of DGLA administration may
have multiple biological benefits for a series of diseases
associated with proliferation. DGLA exert anti-prolifera-
tion action through enhancing free radicals, lipid periox-
idation, PGE1 and 15-HETrE synthesis, which directly or
indirectly influence the cell growth, apoptosis and differ-
entiation mediated by downstream signal transduction
cascades. The consumption of GLA or administration of
DGLA may offer new strategies for treatment and pre-
vention of proliferation and hyperplasia diseases.
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